Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

被引:0
|
作者
Wolff, Robert A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
关键词
Pancreatic cancer; surgery; adjuvant therapy; preoperative therapy; neoadjuvant therapy; chemotherapy; chemoradiation; molecular therapy; PHASE-II TRIAL; FINE-NEEDLE-ASPIRATION; GEMCITABINE-BASED CHEMORADIATION; GROWTH-FACTOR RECEPTOR; LONG-TERM SURVIVAL; PREOPERATIVE CHEMORADIATION; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; RADIATION-THERAPY; POSTOPERATIVE COMPLICATIONS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For over 25 years, the standard of care for resectable pancreatic adenocarcinoma has been upfront surgery followed by delivery of post-operative therapy. Until recently however, there has been no consensus as what constituted a standard adjuvant regimen. Data from large phase III studies now support single agent gemcitabine, administered over 6 cycles, as standard. Nevertheless, the overall survival of patients undergoing upfront surgical resection followed by adjuvant therapy remains poor, with no significant improvements in median, or long term survival over the last 3 decades. Surgery as the first intervention for potentially curative pancreatic cancer has some distinct disadvantages and neoadjuvant therapy provides a mechanism to better select patients for subsequent surgical intervention. Current data suggest this approach spares patients from a morbid surgical procedure when it will be of no benefit and improves outcomes for those who do undergo surgery. Furthermore, with the increasing recognition of borderline resectable pancreatic cancer, neoadjuvant treatment should be considered as alternative to upfront surgery for this distinct clinical entity. This has the potential to maximize the chances of a margin-negative resection and minimize the number of patients harboring aggressive disease from undergoing a fruitless surgical procedure. Importantly, as the number of targeted agents available for clinical use expands, more rational, personalized neoadjuvant therapies may emerge.
引用
收藏
页码:781 / 788
页数:8
相关论文
共 50 条
  • [1] Neoadjuvant treatment concepts for borderline-resectable adenocarcinoma of the pancreas
    MSc, S. Roth
    Mba, M. Schneider
    CHIRURGIE, 2022, 93 (10): : 995 - 996
  • [2] Neoadjuvant Chemoradiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
    Shafi, S.
    Kaubisch, A.
    PANCREAS, 2015, 44 (08) : 1413 - 1413
  • [3] Pathologic Response to Neoadjuvant Chemotherapy and Chemoradiation in Borderline Resectable Adenocarcinoma of the Pancreas
    Lee, Joon K.
    Ghanem, Ahmed I.
    Burmeister, Charlotte
    Jaratli, Hayan
    Raoufi, Mohammad
    Khan, Gazala
    Dobrosotskaya, Irina
    Kwon, David
    Siddiqui, Farzan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E4 - E4
  • [4] Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer
    Kumar, Rachit
    Jabbour, Salma K.
    JOURNAL OF RADIATION ONCOLOGY, 2013, 2 (04) : 353 - 367
  • [5] Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
    Lee, Sang Hoon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 84 (03): : 103 - 110
  • [6] Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma
    Takaori, Ayaka
    Hashimoto, Daisuke
    Ikeura, Tsukasa
    Ito, Takashi
    Nakamaru, Koh
    Masuda, Masataka
    Nakayama, Shinji
    Yamaki, So
    Yamamoto, Tomohisa
    Fujimoto, Kosuke
    Matsuo, Yoshiyuki
    Akagawa, Shohei
    Ishida, Mitsuaki
    Yamaguchi, Kiyoshi
    Imoto, Seiya
    Hirota, Kiichi
    Uematsu, Satoshi
    Satoi, Sohei
    Sekimoto, Mitsugu
    Naganuma, Makoto
    PANCREATOLOGY, 2023, 23 (04) : 367 - 376
  • [7] Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
    Shahda, Safi
    Perkins, Susan
    Cramer, Harvey M.
    House, Michael Garrett
    Nakeeb, Attila
    Zyromski, Nicholas J.
    Ceppa, Eugene P.
    Sehdev, Amikar
    Akisik, Fatih
    Lin, Jingmei
    Schmidt, Christian
    Ellsworth, Susannah G.
    O'Neil, Nina
    Link, Kristen
    O'Neil, Bert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Strategy of Neoadjuvant Therapy for Resectable/Borderline Resectable Pancreatic Cancer
    Hashimoto, D.
    Satoi, S.
    Yamamoto, T.
    Yamaki, S.
    Hirooka, S.
    Ishida, M.
    Ikeura, T.
    Sekimoto, M.
    PANCREAS, 2021, 50 (07) : 1064 - 1064
  • [9] Neoadjuvant therapy in borderline resectable and resectable pancreatic cancer.
    Dhamija, Kriti
    Awuah, Kojo-Frimpong B.
    Marwaha, Alexander
    Kharoud, Harmeet
    Monga, Dulabh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 735 - 735
  • [10] Efficacy of Neoadjuvant Chemotherapy and Radiation in Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kelley, Jesse K.
    Kolbeinsson, Hordur
    Eastburg, Benjamin
    Frisch, Austin
    Khan, Mariam
    Wright, Gerald P.
    Assifi, Mura
    Chandra, Sreenivasa
    Chung, Mathew
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S176 - S177